Injection or surgery — which is this decision really about?

For patients who have been told they have a focal cartilage defect and may need ACI or MACI, the first practical question is rarely about biology — it is about what treatment actually involves. Is this a procedure that requires an operation, a general anaesthetic, and a hospital admission? Or can it be done as an injection?

The answer depends largely on which route is being considered. ChondroFiller injection is delivered as an ultrasound-guided outpatient treatment — a single appointment, no surgical incision, no theatre, and no general anaesthetic required. ACI (autologous chondrocyte implantation) and MACI (matrix-induced ACI) are categorically different: both are two-stage operative procedures. The first stage is an arthroscopic cartilage biopsy; the harvested cells are then cultured in a specialist laboratory over several weeks before a second surgical implantation.

Critically, both approaches address the same underlying problem — focal articular cartilage damage in patients who are not yet candidates for joint replacement. That shared indication is what makes the comparison meaningful. For patients with Grade III or IV focal defects, the question is whether the additional clinical complexity of cell-based surgery provides enough benefit to justify it over an injection-based approach.

How each approach works at the biological level

ChondroFiller injection uses an acellular Type I/III collagen scaffold — no cells are added to the product itself. When the liquid is introduced into the joint, it responds to the neutral pH of the synovial environment and self-polymerises into a dimensionally stable hydrogel within approximately 3–5 minutes. That gel acts as a temporary biological template, drawing in the patient's own repair cells — progenitor cells already present in the joint lining (synovium) and the underlying bone — through a process called matrix-induced chondrogenesis. Over 6–12 months, the scaffold resorbs progressively as new repair tissue forms in its place. Nothing permanent is left behind.

ACI takes a fundamentally different route: the cells themselves do the work, not the scaffold. A biopsy of healthy cartilage (around 200–300 mg) is taken arthroscopically, then sent to a specialist laboratory where the patient's own chondrocytes are expanded over 3–5 weeks. At the second operation, the concentrated cell population is injected under a periosteal patch — a thin flap of tissue sewn over the defect to contain them.

MACI follows the same biopsy-and-culture path but delivers cells pre-seeded onto a porcine collagen membrane, which is fixed into a surgically debrided defect.

Both surgical options are subtractive: the damaged tissue is first cleared away and the defect rebuilt from the base upwards, requiring a clean, dry joint under direct visualisation. ChondroFiller injection is additive — placed into the defect within the natural fluid environment of the joint, working from the top down, without debridement or structural reconstruction.

What the patient journey actually looks like

Recovery and waiting time are where the two pathways diverge most visibly in day-to-day life — and that is where this section picks up, rather than restating the procedural mechanics already covered above.

The ChondroFiller injection appointment encompasses consultation, ultrasound-guided placement, intravenous antibiotic cover, and a discharge plan, all within a single clinic visit. A six-week review is typically included in the package. Because there is no surgical wound, recovery centres on graduated weight-bearing: most patients return to normal walking within days, with activity built up progressively as the scaffold integrates over the following weeks. The biological remodelling continues for six to twelve months, but it does so in the background of ordinary life rather than a structured post-operative programme.

For ACI and MACI, the calendar tells a different story. After the first arthroscopic stage, the patient enters a waiting period — typically three to five weeks — during which the joint remains symptomatic and no active repair has yet begun. Only once the cultured cells are returned from the laboratory does the second, operative stage take place. That second procedure then initiates its own rehabilitation phase: protected weight-bearing, physiotherapy, and a recovery arc shaped by the size of the repaired area and the approach used.

From the decision to proceed, the ChondroFiller injection pathway completes in a single clinic day with a six-week check. The ACI or MACI pathway spans a minimum of six weeks between its first and final operative stage — before post-surgical rehabilitation has even started.

Which patients are suitable for each treatment

The indication profiles for these two routes differ in ways that matter at the point of clinical decision-making.

ACI and MACI carry well-defined parameters: focal defects typically between 2 and 10 cm², patients who are younger and active enough to commit to a structured rehabilitation programme, healthy cartilage borders around the lesion, and satisfactory joint alignment. Those boundaries are partly a constraint and partly a strength — the evidence underpinning both techniques is drawn from exactly that population, so outcomes data are reasonably reliable for patients who fit the criteria.

ChondroFiller injection is described by the manufacturer as carrying no upper age limit and no formal defect-size ceiling, and it targets Grade III and IV focal articular lesions. That positions it as the broader nominal indication — applicable in older patients or in joints where defect geometry falls outside the surgical template. However, the 'no defect-size limit' claim has not been validated in controlled trials directly comparing ChondroFiller injection with ACI or MACI for larger lesions, and that gap in the evidence should weigh on any decision about complex or extensive defects.

Both routes are intended for focal pathology. Patients with diffuse joint-surface loss are managed through separate pathways — this distinction carries over from the outset of any cartilage consultation.

Age, activity level, alignment, defect borders, and overall joint health all bear on which route — if either — is clinically appropriate. That balance requires an assessment rather than self-selection.

What the outcome data shows — and where the evidence gaps are

Published figures give a consistent picture across both routes for functional improvement: ChondroFiller injection and ACI/MACI each produce roughly 30 points of gain on the IKDC score in their respective study populations. On that primary functional measure, neither approach clearly outperforms the other in the available data. Where the figures diverge is on reoperation: published series report a rate of approximately 3–8% for ChondroFiller injection, against rates running up to 37% for ACI and MACI. Symptom-relief success for ChondroFiller injection is quoted at 70–85% across available sources — a figure broadly comparable to established cartilage interventions.

Those numbers are real, and the difference in reoperation burden is clinically significant. What the evidence cannot yet settle is whether that gap reflects genuine biological superiority or simply the fact that the two patient populations have never been compared in the same trial. ChondroFiller injection RCTs have been controlled against microfracture, not against ACI or MACI, so the datasets underlying each modality are drawn from studies with different comparators, different selection criteria, and potentially different defect profiles. The reoperation differential may partly reflect who received each treatment, not only how the treatment performed.

The second gap is longitudinal. No independent follow-up data beyond two years for ChondroFiller injection is available in current published sources. ACI and MACI have been used clinically since 1994, and medium-to-long-term durability data for cell-based repair are more established. That imbalance is worth stating plainly: ChondroFiller injection's shorter published track record is a genuine uncertainty, not a rounding error, and it bears on any discussion of durability for younger or more active patients.

Cost, access, and taking the next step in London

Guide costs for ChondroFiller injection in the UK run from approximately £3,000 to £8,000 — the London Cartilage Clinic price includes consultation, ultrasound guidance, the product itself, intravenous antibiotic cover, and a six-week follow-up appointment. Costs should always be confirmed with the treating clinic; these are guide figures, not fixed prices. ChondroFiller injection is not currently NHS-funded and is not covered by Bupa or AXA; it is accessed on a fully self-funded basis.

For context, ACI and MACI private fees in the UK typically range from £7,000 to £14,000; STACi — the single-stage, 3D-scaffold cell implantation variant — is quoted at approximately £28,000 privately, reflecting its intraoperative laboratory complexity.

In the UK, ChondroFiller injection is delivered at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads its delivery. In any image-guided procedure, the practitioner's clinical experience is a material factor in outcomes, not a formality.

The comparison set out across this article does not resolve into a straightforward winner. ChondroFiller injection offers a considerably simpler patient journey and a lower cost ceiling than cell-based surgery; ACI and MACI carry a longer published track record and more established durability data. Those are genuine trade-offs, not marketing positions on either side. What they point toward is the same conclusion the evidence gaps do: a specialist assessment remains the only reliable way to determine whether a specific defect, joint, and patient profile actually suits either route. Assessments at the London Cartilage Clinic on Harley Street can be requested at londoncartilage.com.